CONMED shares are trading lower after the company reported worse-than-expected Q2 revenue results and lowered its FY24 guidance. Additionally, Needham lowered its price target on the stock from $106 to $97.
Portfolio Pulse from Benzinga Newsdesk
CONMED shares are trading lower after the company reported worse-than-expected Q2 revenue results and lowered its FY24 guidance. Additionally, Needham lowered its price target on the stock from $106 to $97.
August 01, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CONMED shares are trading lower due to disappointing Q2 revenue results and a reduction in FY24 guidance. Needham also lowered its price target from $106 to $97.
The combination of worse-than-expected Q2 revenue results, lowered FY24 guidance, and a reduced price target from Needham is likely to negatively impact CONMED's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100